Pan Xinchao, the Executive Deputy Director of Standing Committee of the Dongguan Municipal People's Congress, Led the Team to Visit Great Bay Bio
August 28th，2019 Press Release
Pan Xinchao, the Executive Deputy Director of Standing Committee of the Dongguan Municipal People's Congress, led the team to visit high-end talent in Great Bay Bio
[Aug. 28th, 2019 – DONG GUAN] Pang Xinchao, the Executive Deputy Director of Standing Committee of the Dongguan Municipal People's Congress, and Zhao Yi, the Deputy Director of Dongguan Municipal Human Resources and Social Security Bureau, and Deng Weijie, the Chief of Technology Transformation and Regional Innovation Sector of Dongguan Municipal Science and Technology Bureau, and Zhu Mohe, the Vice Secretary of the Changping Town Party Committee, led the team to visit high-end talent in Great Bay Bio, and to exchange ideas.
Dr. Chen Liang, the CEO of Great Bay Bio, and Dr. Wang Yonggang, the Vice President, and others warmly welcomed visitors and showed them around the company R&D center, the office area, etc. Dr. Chen Liang introduced company, recent development status, and future planning in the conference for visitors, and showed the blueprint that Great Bay Bio could solve two big headaches in the biotechnology industry with its unprecedented AI + biotechnology development team and platform. With such, Great Bay Bio could disruptively shorten timeline for drug development, dramatically lower development cost. Dr. Wang Yonggang gave visitors detailed introduction for R&D innovative technology, and received very positive feedback. Officers after conference showed thanks for and compliment the Great Bay Bio for its high-end management team and R&D capability; Pang Xinchao are very pleased that overseas returnees to start up business with their new technology and ideas, and has high expectation for Great Bay Bio which is answering the development of Great Bay Area greatly supported by the Government.
About Great Bay Bio
Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise developing biologics with AI technologies. Since its foundation, it has been committed to biotech and biologics development. It has founded Dongguan Taili Biotech Co., Ltd. and Guangzhou Taili Biomedical Technology Co., Ltd. Investing more than RMB 300 million, the company has successfully established the independent and integrated technology platform for drug R&D and large-scale preparation. Through customized CMC packaging services, it has successfully helped several products reach NDA stage, some of which are national class I new drugs.
GBB positions itself as a Contract Development and Manufacturing Organization (CDMO), applying AI technology to CMC (Chemistry, Manufacturing, Control) platform for drug development, which targets the drawbacks of drug development including long timeline and high costs, and solves them with the AI+CMC model. Based on massive datum obtained from conventional biologics development, CMC platform can build models and conduct AI analyses. Integrating AI and biotechnology, it can overcome hurdles in biologics development and greatly reduce the time and costs so as to provide much cheaper, efficient and high-quality drug development service for the clients, and also bring much economical drug to the society.
GBB has been recognized as the Patent Incubation Company, Patent Pilot Company, National High-tech Company, Dongguan New Research Institution, Guangdong Top Ten Foreign R&D Center, Guangdong R&D Center of Genetic Engineering Medicine and Engineering, and Guangdong Doctoral Workstation. Since 2006, it has undertaken a number of government projects. More than RMB 20 million has been received from the government to support its provincial and national projects, such as Guangdong-Hong Kong Key Breakthrough Project and National Major New Drug Projects.
The CMC platform has an area of over 3100 m2 and a whole set of advanced biopharmaceutical R&D equipment. The key equipment has been purchased from world-renowned manufacturers such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot workshop is designed strictly in accordance with cGMP requirements, mainly at the C level and some even at the A level.
For more details, please visit：www.greatbay-bio.com
Contact for business：email@example.com
Contact for media and investment: firstname.lastname@example.org